Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy

BACKGROUND: Treatment with anti-PD1 monoclonal antibodies improves the survival of metastatic melanoma patients but only a subgroup of patients benefits from durable disease control. Predictive biomarkers for durable benefit could improve the clinical management of patients. METHODS: Plasma samples...

Descripción completa

Detalles Bibliográficos
Autores principales: Seremet, Teofila, Jansen, Yanina, Planken, Simon, Njimi, Hassan, Delaunoy, Mélanie, El Housni, Hakim, Awada, Gil, Schwarze, Julia Katharina, Keyaerts, Marleen, Everaert, Hendrik, Lienard, Danielle, Del Marmol, Véronique, Heimann, Pierre, Neyns, Bart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727487/
https://www.ncbi.nlm.nih.gov/pubmed/31488153
http://dx.doi.org/10.1186/s12967-019-2051-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727487/
https://www.ncbi.nlm.nih.gov/pubmed/31488153
http://dx.doi.org/10.1186/s12967-019-2051-8

Ejemplares similares